For now, some industry self-regulators are keeping an eye on the trend
This new molecule, by acting synergistically on combined systems known to be altered in T2DM [33, 34], could indeed expand the therapeutic potential of GLP-1 agonists/analogues, suggesting new scenarios in terms of improving glycemic control, weight management, and hopefully providing protection against chronic micro-macrovascular complications and not only limited to hepatic complications
FDA scrutiny on GLP-1 compounders and tele-health firms is rapidly increasing
Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients
As anticipated, patient preference is towards GLP-1 RA profiles associated with less frequent dosing, with once-weekly preferred to once-daily, with the latter preferred over twice-daily [123,124,125]